Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSkin dryness is not listed among Wegovy's common side effects in its UK prescribing information, but some people starting semaglutide do report changes to skin texture or moisture. The evidence points mainly to dehydration from nausea and reduced fluid intake as the most likely culprit, rather than a direct pharmacological effect on the skin itself. This page walks through what the clinical data actually shows, why dehydration matters on GLP-1 treatment, and what to watch for. Wegovy is a prescription-only medicine; a prescriber decides whether it suits you following a clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Wegovy Summary of Product Characteristics, published on the electronic Medicines Compendium, lists its side-effect profile in detail. Nausea, vomiting, diarrhoea, constipation, indigestion and fatigue feature prominently, these are the effects that dominate the early weeks of treatment. Skin dryness as a standalone adverse reaction does not sit in the common or very common categories. That matters, because the SmPC draws on the large clinical trial programme and post-marketing surveillance; effects seen frequently enough to be attributable to the medicine are included. The NHS medicines page for semaglutide echoes this, listing the GI effects as the ones most people experience, particularly after starting treatment or a dose increase.
That does not mean no one experiences dry skin. If you are asking whether Wegovy can cause dry skin, post-marketing reports cover a wide range of events, and the absence from the common-effects list tells you it happens rarely, not never. The more useful question is: when dry skin does occur, what is driving it?
The mechanism here is straightforward. Wegovy slows gastric emptying and suppresses appetite via GLP-1 receptor activation. In the early weeks, nausea is common enough that many people eat and drink noticeably less. If vomiting or diarrhoea also occur, fluid losses accelerate. Skin is one of the first organs to reflect even mild dehydration, it loses elasticity, feels tight and may look dull or flaky. This is a hydration effect, not a direct dermatological one.
A simple check: press gently on the skin on the back of your hand for a couple of seconds, then release. Healthy hydrated skin springs back almost instantly. If it takes a beat longer to flatten, that sluggishness can indicate you need more fluid. It takes under a minute and costs nothing. Aiming for consistent water intake throughout the day, especially during weeks when nausea is active, addresses the root cause rather than just the symptom. If you are finding it hard to keep fluids down, that is worth raising with your prescriber, persistent vomiting leading to dehydration can affect kidney function and warrants clinical input.
For a closer look at the relationship between semaglutide and skin hydration specifically, our semaglutide and dry skin page covers the broader evidence in more depth.
Dry, slightly tight skin in the early weeks of treatment is different from persistent itch, spreading redness or a raised rash. Itching on Wegovy can have several origins: very dry skin is one; an injection-site reaction is another (mild localised redness or itching at the injection spot is documented); and, less commonly, a broader hypersensitivity reaction. The STEP 1 phase 3 trial (1,961 adults with obesity, 68 weeks, published in the New England Journal of Medicine) captured adverse events rigorously, and serious allergic reactions were rare but did occur, consistent with all injectable medicines.
If itching is mainly at the injection site and resolves within a day or two, rotating sites and ensuring the pen has been at room temperature for a moment before injection can help. If itching is widespread, if there is swelling around the face or throat, or if breathing changes, that is an emergency. For questions specifically about itch as a symptom, our page on whether Wegovy can make your skin itch covers the differentiation in more detail.
Changes to oral and nasal mucosa sometimes accompany reduced food and fluid intake too. Some people on semaglutide notice mouth dryness; there is a separate page on Wegovy and dry mouth if that is also a concern.
For most people, our guide to Wegovy and dry skin explains how skin dryness linked to early GI side effects improves as those effects settle, typically within the first few weeks, though the timeline varies. In the meantime, maintaining fluid intake, using an unfragranced moisturiser if skin feels tight, and not cutting calories so severely that protein intake drops (protein is critical for skin integrity) are all sensible measures. The Wegovy overview page explains how the titration schedule works and why the first months of treatment tend to be the most symptom-heavy.
If skin changes persist beyond the initial adjustment period, appear unrelated to hydration, or cause you genuine concern, your prescriber should know. That includes any new rash, significant itch or unexpected changes to skin texture that do not resolve. You can also report suspected side effects, however minor they seem, through the MHRA's Yellow Card scheme, the data collected helps regulators build a fuller picture of how medicines behave in real-world use.
If you are considering starting Wegovy and want to understand the full side-effect profile before making a decision, our prescribers at nume's free consultation are there to answer exactly this kind of question, your consultation is reviewed the same day by a GPhC-registered prescriber, not a decision algorithm.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.